Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Diaceutics ( (GB:DXRX) ) just unveiled an announcement.
Diaceutics PLC announced that Delia Keeling, closely associated with the company’s Chair, Peter Keeling, sold 500,000 ordinary shares at 126 pence each. This transaction reduces the Keelings’ combined shareholding to approximately 17.98% of the company’s issued share capital. This sale is significant as it reflects a change in the major holdings of the company, potentially impacting its market perception and shareholder dynamics.
The most recent analyst rating on (GB:DXRX) stock is a Buy with a £200.00 price target. To see the full list of analyst forecasts on Diaceutics stock, see the GB:DXRX Stock Forecast page.
More about Diaceutics
Diaceutics PLC is a prominent technology and solutions provider in the pharma and biotech industry. The company offers an end-to-end commercialization solution for precision medicines through its DXRX platform, which integrates data analytics, scientific, and advisory services. Diaceutics focuses on ensuring that patients receive the appropriate tests and therapies to improve their disease outcomes.
Average Trading Volume: 114,460
Technical Sentiment Signal: Buy
Current Market Cap: £114.1M
For detailed information about DXRX stock, go to TipRanks’ Stock Analysis page.